Cargando…
Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease
BACKGROUND: A residual risk of cardiovascular disease tends to persist despite standard prevention therapy with statins. This may stem partly from increased oxidized low-density lipoprotein (LDL) levels. However, how oxidized LDL can be further reduced beyond statin therapy in high-risk diabetes pat...
Autores principales: | Matsuda, Morihiro, Tamura, Ritsu, Kanno, Kotaro, Segawa, Takatsugu, Kinoshita, Haruyuki, Nishimoto, Orie, Nishiyama, Hirohiko, Kawamoto, Toshiharu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029151/ https://www.ncbi.nlm.nih.gov/pubmed/24314067 http://dx.doi.org/10.1186/1758-5996-5-77 |
Ejemplares similares
-
Cardiovascular Risk Management With Liaison Critical Path in Japan: Its Effects on Implementation of Evidence-Based Prevention in Practice
por: Matsuda, Morihiro, et al.
Publicado: (2012) -
Serum malondialdehyde level: Surrogate stress marker in the Sikkimese diabetics
por: Bhutia, Yazum, et al.
Publicado: (2011) -
Serum lysophospholipid levels are altered in dyslipidemic hamsters
por: Suárez-García, Susana, et al.
Publicado: (2017) -
Association of bilirubin and malondialdehyde levels with retinopathy in type 2 diabetes mellitus
por: Dave, Apoorva, et al.
Publicado: (2015) -
Thyroid volumes and serum VEGF levels in dyslipidemic patients: effects of statin treatment
por: AYDIN, Kadriye, et al.
Publicado: (2019)